GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Voyageur Pharmaceuticals Ltd (TSXV:VM) » Definitions » Capex-to-Operating-Income

Voyageur Pharmaceuticals (TSXV:VM) Capex-to-Operating-Income : 0.00 (As of Feb. 2024)


View and export this data going back to 2012. Start your Free Trial

What is Voyageur Pharmaceuticals Capex-to-Operating-Income?

Capex-to-Operating-Income measures a company's investments in physical assets such as property, industrial buildings or equipment to its operating income.

Voyageur Pharmaceuticals's Capital Expenditure for the three months ended in Feb. 2024 was C$0.00 Mil. Its Operating Income for the three months ended in Feb. 2024 was C$-0.33 Mil.

GuruFocus do not calculate Capex-to-Operating-Income if the Operating Income is negative.


Voyageur Pharmaceuticals Capex-to-Operating-Income Historical Data

The historical data trend for Voyageur Pharmaceuticals's Capex-to-Operating-Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Voyageur Pharmaceuticals Capex-to-Operating-Income Chart

Voyageur Pharmaceuticals Annual Data
Trend Dec14 Dec15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23
Capex-to-Operating-Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Voyageur Pharmaceuticals Quarterly Data
May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Capex-to-Operating-Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Voyageur Pharmaceuticals's Capex-to-Operating-Income

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Capex-to-Operating-Income, along with its competitors' market caps and Capex-to-Operating-Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Voyageur Pharmaceuticals's Capex-to-Operating-Income Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Capex-to-Operating-Income distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Capex-to-Operating-Income falls into.



Voyageur Pharmaceuticals Capex-to-Operating-Income Calculation

Voyageur Pharmaceuticals's Capex-to-Operating-Income for the fiscal year that ended in Nov. 2023 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -1.346
=N/A

Voyageur Pharmaceuticals's Capex-to-Operating-Income for the quarter that ended in Feb. 2024 is calculated as

Capex-to-Operating-Income=- Capital Expenditure / Operating Income
=- (0) / -0.329
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Voyageur Pharmaceuticals  (TSXV:VM) Capex-to-Operating-Income Explanation

Capex-to-Operating-Income assesses how much emphasis a company is placing upon investing in capital-intensive projects. The ratio is generally a good gauge to quantify how much focus on growth a company has. Typically, smaller companies that are still growing and expanding will have a higher Capex to Operating Income Ratio, since such businesses are likely investing more in physical assets. Lower ratios could indicate that a company has reached maturity and it is no longer pursuing aggressive growth.


Voyageur Pharmaceuticals Capex-to-Operating-Income Related Terms

Thank you for viewing the detailed overview of Voyageur Pharmaceuticals's Capex-to-Operating-Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Voyageur Pharmaceuticals (TSXV:VM) Business Description

Traded in Other Exchanges
Address
333 Southwest 7th Avenue, Suite 800, Calgary, AB, CAN, T2P 2Z1
Voyageur Pharmaceuticals Ltd is engaged in the development of pharmaceutical ingredients (API) minerals. The company focuses on developing barium and iodine radiocontrast products and bromine-based pharmaceutical products. It provides its products for medical applications and diagnostics.
Executives
Charles Littlejohn 10% Security Holder

Voyageur Pharmaceuticals (TSXV:VM) Headlines

No Headlines